Haleon (NYSE:HLN) Stock Rating Lowered by Zacks Research

Haleon (NYSE:HLN) was downgraded by Zacks Research from a “hold” rating to a “strong sell” rating in a report released on Tuesday,Zacks.com reports.

A number of other brokerages have also recently issued reports on HLN. Weiss Ratings reissued a “hold (c)” rating on shares of Haleon in a research note on Tuesday, June 30th. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Haleon in a research note on Thursday, April 30th. Rothschild & Co Redburn downgraded shares of Haleon from a “strong-buy” rating to a “hold” rating in a report on Tuesday, June 16th. Finally, Wall Street Zen raised shares of Haleon from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy”.

Haleon Price Performance

NYSE HLN opened at $9.86 on Tuesday. Haleon has a 12 month low of $8.65 and a 12 month high of $11.28. The stock has a market cap of $43.41 billion, a price-to-earnings ratio of 25.27, a PEG ratio of 2.29 and a beta of 0.13. The company’s 50 day moving average is $9.33 and its two-hundred day moving average is $9.85. The company has a current ratio of 0.92, a quick ratio of 0.71 and a debt-to-equity ratio of 0.47.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in HLN. Fiduciary Financial Group LLC purchased a new position in shares of Haleon during the second quarter valued at about $97,000. GAMMA Investing LLC lifted its position in shares of Haleon by 18.1% in the second quarter. GAMMA Investing LLC now owns 34,810 shares of the company’s stock worth $325,000 after buying an additional 5,338 shares in the last quarter. Arlington Partners LLC lifted its position in shares of Haleon by 23.0% in the second quarter. Arlington Partners LLC now owns 29,826 shares of the company’s stock worth $278,000 after buying an additional 5,580 shares in the last quarter. Pacific Excel Wealth Advisors Inc. purchased a new stake in shares of Haleon in the second quarter worth about $209,000. Finally, Hilltop National Bank boosted its stake in Haleon by 12.7% during the second quarter. Hilltop National Bank now owns 15,672 shares of the company’s stock valued at $146,000 after buying an additional 1,771 shares during the last quarter. Institutional investors own 6.67% of the company’s stock.

About Haleon

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over?the?counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self?care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.